文献速递呼吸危重症与机械通气呼吸道感染

脓毒症相关ARDS炎症亚型的6个月和12个月患者结局:SAILS-ALTOS试验二次分析

Six-month and 12-month patient outcomes based on inflammatory subphenotypes in sepsis-associated ARDS: secondary analysis of SAILS-ALTOS trial.
PubMed 文献 · Thorax · 2021-06-10

该研究基于SAILS-ALTOS试验568例脓毒症相关ARDS患者,比较高炎症与低炎症亚型对6个月和12个月患者报告结局的影响。高炎症亚型12个月累积生存率低于低炎症亚型(58% vs 72%,p<0.01),但90天以后生存率无显著差异(86% vs 89%,p=0.70)。多数幸存者存在多维度功能受损,但两亚型在6个月和12个月的身体、心理和认知结局上无一致的重要差异。

要点

  • 高炎症亚型12个月累积生存率低于低炎症亚型,但90天后生存率无显著差异。
  • 多数幸存者存在身体、心理或认知功能受损,两亚型间无一致重要差异。
  • 炎症亚型主要反映急性期疾病及其短期影响,对远期结局预测价值有限。

核心结论

  • 高炎症与低炎症ARDS亚型在90天以后生存率无显著差异,6个月和12个月身体、认知和心理健康结局也无一致的重要差异。
  • 炎症亚型主要反映急性期疾病及其短期影响,对远期患者报告结局的区分价值有限。

研究设计与样本

  • SAILS-ALTOS试验的二次分析,纳入568例脓毒症相关ARDS患者,随机接受瑞舒伐他汀或安慰剂并分配炎症亚型。
  • 6个月和12个月幸存者分别为232例和219例(共243例独特幸存者),评估亚型与患者报告结局的关联。
  • 部分患者子集接受基于表现的体能测试(如6分钟步行试验)和认知评估。

主要发现

  • 高炎症亚型与低炎症亚型相比,12个月累积生存率更低(58% vs 72%,p<0.01)。
  • 90天以后生存率在高炎症与低炎症亚型间无显著差异(86% vs 89%,p=0.70)。
  • 6个月时,低炎症与高炎症亚型患者报告SF-36心理健康领域评分中位数(IQR)分别为47(33-56)与44(35-56)(p=0.99)。
  • 6个月时,低炎症与高炎症亚型6分钟步行距离占预计值百分比分别为66%(48%,80%)与66%(49%,79%)(p=0.76)。

临床怎么用

  • 对脓毒症相关ARDS幸存者的远期随访应关注身体、心理和认知功能,不应仅依据急性期炎症亚型预判远期结局。
  • 高炎症亚型患者急性期死亡风险较高,但存活至90天后其远期结局与低炎症亚型无显著差异。

局限性

  • 本研究为SAILS-ALTOS试验的二次分析,亚型与远期结局的关联非随机化比较。
  • 6个月和12个月幸存者样本量分别降至232例和219例,可能影响远期结局比较的统计效能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prior acute respiratory distress syndrome (ARDS) trials have identified hypoinflammatory and hyperinflammatory subphenotypes, with distinct differences in short-term outcomes. It is unknown if such differences extend beyond 90 days or are associated with physical, mental health or cognitive outcomes. METHODS: 568 patients in the multicentre Statins for Acutely Injured Lungs from Sepsis trial of rosuvastatin versus placebo were included and assigned a subphenotype. Among 6-month and 12-month survivors (N=232 and 219, respectively, representing 243 unique survivors), subphenotype status was evaluated for association with a range of patient-reported outcomes (eg, mental health symptoms, quality of life). Patient subsets also were evaluated with performance-based tests of physical function (eg, 6 min walk test) and cognition. FINDINGS: The hyperinflammatory versus hypoinflammatory subphenotype had lower overall 12-month cumulative survival (58% vs 72%, p<0.01); however, there was no significant difference in survival beyond 90 days (86% vs 89%, p=0.70). Most survivors had impairment across the range of outcomes, with little difference between subphenotypes at 6-month and 12-month assessments. For instance, at 6 months, in comparing the hypoinflammatory versus hyperinflammatory subphenotypes, respectively, the median (IQR) patient-reported SF-36 mental health domain score was 47 (33-56) vs 44 (35-56) (p=0.99), and the per cent predicted 6 min walk distance was 66% (48%, 80%) vs 66% (49%, 79%) (p=0.76). INTERPRETATION: Comparing the hyperinflammatory versus hypoinflammatory ARDS subphenotype, there was no significant difference in survival beyond 90 days and no consistent findings of important differences in 6-month or 12-month physical, cognitive and mental health outcomes. These findings, when considered with prior results, suggest that inflammatory subphenotypes largely reflect the acute phase of illness and its short-term impact.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Hashem MD, Hopkins RO, Colantuoni E, et al. Six-month and 12-month patient outcomes based on inflammatory subphenotypes in sepsis-associated ARDS: secondary analysis of SAILS-ALTOS trial. Thorax. 2021. PMID: 34112703. doi:10.1136/thoraxjnl-2020-216613

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。